Alumis announces Phase 1 data for CNS penetrant TYK2 inhibitor, A-005

Alumis (ALMS) announced data from a Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics, PK, of single- and multiple-ascending doses of A-005, a potent, selective, central nervous system, CNS, penetrant TYK2 inhibitor, in healthy participants. In the clinical trial, A-005 was well tolerated with no serious adverse events reported. A-005 demonstrated the ability to penetrate into the CNS with significant and prolonged exposure in the cerebral spinal fluid. A-005 levels in the CSF were comparable to or exceeded the free drug exposure in plasma and exceeded IC90 levels in cell-based assays.